Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) posted its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10, Briefing.com reports. Isotechnika Pharma had a negative net margin of 16,855.24% and a negative return on equity of 17.54%. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same period last year, the firm posted ($0.11) earnings per share. The business’s revenue was up .0% on a year-over-year basis.
Shares of NASDAQ AUPH opened at $5.15 on Friday. Isotechnika Pharma has a 52-week low of $4.41 and a 52-week high of $8.19.
A number of research analysts have recently weighed in on AUPH shares. Cantor Fitzgerald set a $16.00 price target on shares of Isotechnika Pharma and gave the company an “overweight” rating in a report on Thursday, March 15th. ValuEngine upgraded shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. BidaskClub upgraded shares of Isotechnika Pharma from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. Zacks Investment Research lowered shares of Isotechnika Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Finally, Royal Bank of Canada began coverage on shares of Isotechnika Pharma in a report on Thursday, February 8th. They set an “outperform” rating and a $9.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Isotechnika Pharma presently has an average rating of “Buy” and an average price target of $10.93.
WARNING: “Isotechnika Pharma (AUPH) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/aurinia-pharmaceuticals-auph-announces-quarterly-earnings-results-beats-expectations-by-0-10-eps.html.
About Isotechnika Pharma
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.